Modern treatment for nasopharyngeal carcinoma: Current status and prospects

Current Opinion in Oncology

Volumn 23, Issue 3, 2011, Pages 254-258

  Rottey, Sylvie ^a   Madani, Indira ^b   Deron, Philippe ^b   Van Belle, Simon ^a  

^a Department of Medical Oncology ^*  (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

chemoradiotherapy; Epstein Barr virus; intensity modulated radiotherapy; nasopharyngeal carcinoma; targeted therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

AREA UNDER THE CURVE; CANCER RECURRENCE; CLINICAL TRIAL; EPSTEIN BARR VIRUS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; REVIEW; VIRAL CLEARANCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DNA, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; NASOPHARYNGEAL NEOPLASMS; NEOADJUVANT THERAPY; TREATMENT OUTCOME;

EID: 79955032392     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328344f527     Document Type: Review

References (33)

1. Chan AT. Nasopharyngeal carcinoma. Ann Oncol 2010; 21 (Suppl 7): vii308-vii312.
2. Chan AT, Grégoire V, Lefebvre JL, et al., EHNS-ESMO-ESTRO Guidelines Working Group. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5):v187-v189.
3. Wang WY, Twu CW, Chen HH, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010; 16:1016-1024.
4. Hutajulu SH, Hariwiyanto B, Herdini C, et al. Analysis of antibodies Epstein-Barr virus and viral DNA quantification as early screening tools of nasopharyngeal carcinoma [abstract 1037p]. ESMO Congress, 8-12 October 2010; Milan, Italy.
5. Veldeman L, Madani I, Hulstaert F, et al. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008; 9:367-375. (Pubitemid 351411653)
6. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006; 66:981-991. (Pubitemid 44633504)
7. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007; 25:4873-4879. (Pubitemid 350220416)
8. Wang SZ, Li J, Miyamoto CT, et al. A study of middle ear function in the treatment of nasopharyngeal carcinoma with IMRT technique. Radiother Oncol 2009; 93:530-533.
9. Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 2009; 27:3684-3690.
10. Xiao WW, Huang SM, Han F, et al. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modu lated accelerated radiotherapy combined with cisplatin concurrent chemo therapy: long-term results of a phase 2 study. Cancer 2010. [Epub ahead of print]
11. Su SF, Han F, Zhao C, et al. Long-term outcomes of early-stage nasophar- yngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print]
12. Tham IW, Lin S, Pan J, et al. Intensity-modulated radiation therapy without concurrent chemotherapy for stage IIb nasopharyngeal cancer. Am J Clin Oncol 2010; 33:294-299.
13. Wang W, Yang H, Hu W, et al. Clinical study of the necessity of replanning before the 25th fraction during the course of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2010; 77:617-621.
14. Zhao L, Wan Q, Zhou Y, et al. The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol 2011; 98:23-27.
15. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemo radiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998; 16:1310-1317. (Pubitemid 28175745)
16. Hu W, Ding W, Yang H, et al. Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma. Radiother Oncol 2009; 93:488-491.
17. Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally ad vanced nasopharyngeal carcinoma. J Natl Cancer Inst 2010; 102:1188-1198.
18. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27:242-249.
19. Guo L, Lin HX, Xu M, et al. Phase I study of TPF neoadjuvant chemotherapy followed by radical radiotherapy in advanced nasopharyngeal carcinoma. Chin J Cancer 2010; 29:136-139.
20. Airoldi M, Gabriele P, Gabriele AM, et al. Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carbo-platin+taxol in locally advanced nasopharyngeal carcinoma. Cancer Che mother Pharmacol 2010. [Epub ahead of print]
21. Zheng J, Wang G, Yang GY, et al. Induction chemotherapy with nedaplatin with 5-FU followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Jpn J Clin Oncol 2010; 40:425-431.
22. Bae WK, Hwang JE, Shim HJ, et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. Cancer Chemother Pharmacol 2010; 65:589-595.
23. Kerboua E, Lagha N, Bouzid K, et al. Induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by concomitant cisplatin plus radiotherapy in locally advanced nasopharyngeal cancer [abstract 1040]. ESMO Congress; 8-12 October 2010; Milan, Italy.
24. Yamouni M, Beldjilali Y, Benhadji KA, et al. A phase II trial of induction chemotherapy with cisplatin, docetaxel and capecitabine followed by concurrent cisplatin-radiotherapy in advanced nasopharyngeal carcinoma [abstract 1041]. ESMO Congress; 8-12 October 2010; Milan, Italy.
25. Ekenel M, Keskin S, Basaran M, et al. Clinical outcomes in patients with locally advanced nasopharyngeal cancer treated with neoadjuvant docetaxel and cisplatin followed by radiation treatment and concomitant cisplatin [supplementary abstract e16017]. J Clin Oncol 2010; 28
26. Numico G, Airoldi M, Gabriele P, et al. Induction chemotherapy with carboplatin and paclitaxel followed by radiotherapy and concurrent weekly carboplatin plus paclitaxel in locally advanced nasopharyngeal carcinoma in a nonendemic population [supplementary abstract 5569]. J Clin Oncol 2010; 28:15s.
27. Razak AR, Siu LL, Le Tourneau C. Molecular targeted therapies in all histologies of head and neck cancers: an update. Curr Opin Oncol 2010; 22:212-220.
28. MaBB, Lui VW, Poon FF, et al. Preclinical activity of gefitinib in nonkeratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Invest New Drugs 2010; 28:326-333.
29. Huang Y, Wang Y, Li Y, et al. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG(2). J Cancer Res Clin Oncol 2010. [Epub ahead of print]
30. Hui EP, Lui VW, Wong CS, et al. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Invest New Drugs 2010. [Epub ahead of print]
31. Lee N, Zhang Q, Kim J. Phase II study of concurrent and adjuvant chemotherapy with intensity-modulated radiation therapy of three-dimensional conformal radiotherapy+ bevacizumab for locally or regionally advanced nasopharyngeal cancer [RTOG 0615]: preliminary toxicity report. Int J Radiat Oncol Biol Phys 2010; 78(3 Suppl):221.
32. Lim WT,Thng C, Toh CK, et al. A phase II study of GW786034 (pazopanib) in Asian patients with recurrent/metastatic undifferentiated nasopharyngeal carcinoma [supplementary abstract 5556]. J Clin Oncol 2010; 28:15s.
33. Lu T, Zhao C, Chen C, et al. An open, multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma (NPC): preliminary report [supplementary abstract 5577]. J Clin Oncol 2010; 28:15s.